Immuno-Oncology Therapy Market To Report Impressive Growth, Revenue To Surge To US$ 97.34 Billion By 2022

10-Oct-2018 | Zion Market Research

With the presence of a large pool of participants, the global immuno-oncology therapy market is displaying a highly competitive business landscape, finds a new research report by Zion Market Research (ZMR). Amgen Inc., Novartis AG, Pfizer, Incorporation, AstraZeneca Plc., Bristol-Myers Squibb Company, Eli-Lilly and Company, F.Hoffmann-La Roche Ltd, and GlaxoSmithKline Plc are some of the key vendors of immuno-oncology therapy across the world. These players are focusing aggressively on innovation, as well as on including advanced technologies in their existing products. Over the coming years, they are also expected to take up partnerships and mergers and acquisitions as their key strategy for business development states the immuno-oncology therapy market study.

Citing an instance, on September 24, 2018, Transgene—a France based biotech firm developing virus-based immunotherapy against cancers and contagious ailments—introduced myvacTM, a personalized viral vector-based immunotherapy against cancer projected to enter clinical development during 2019.

Request Sample Request Customization Buy Now

This review is based on a report by Zion Market Research, titled  Immuno-oncology Therapy Market by Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines) and by Therapeutic Areas, for Hospitals, Clinics, ASC’s and Cancer Research Institutes: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022.”- https://www.zionmarketresearch.com/report/immuno-oncology-therapy-market

Global Immuno oncology Therapy Market

As estimated in this report, the global immuno-oncology therapy market stood at US$ 42.97 billion in 2016. Witnessing a tremendous rise during the period from 2017 to 2022, the revenue in this immuno-oncology therapy market is expected to reach US$ 97.34 billion by the end of the forecast period.

Massive Surge In Cancer Incidences To Enhance Market Scope

“Rise in cancer cases, technological innovation in cancer treatments, and rise in cancer research activities are anticipated to largely impact the growth of immuno-oncology therapy market in the near future,” says the author of this study. Apart from this, a shift from conventional chemotherapy to immunotherapy along with the need for treating many forms of cancers such as lung cancer, skin cancer, and breast cancer are predicted to boost immuno-oncology therapy market trends. In addition, the launching of new drug classes such as monoclonal antibodies and HDAC inhibitors are expected to create profit-making opportunities for immuno-oncology therapy market in the coming years.

Shortage of experienced healthcare experts, high treatment costs, and lack of awareness about the immuno-oncology therapy among the patient population base, however, can hinder the progress of immuno-oncology therapy market over the coming years. Nevertheless, growing investments in healthcare activities along with large-scale registration with health insurance firms covering cancer treatment is expected to propel immuno-oncology therapy market revenue in the years ahead.

Accessibility Of New Cancer Drugs To Support North American Dominance

Regionally, North America has been leading the worldwide immuno-oncology therapy market and is anticipated to continue on the dominant position in the years to come, states the immuno-oncology therapy market study. Growing occurrence of cancer and the easy availability of modern therapeutics in the region is the main factor behind the dominance of the North America immuno-oncology therapy market. The high number of market players being headquartered in North America is another significant factor that is supporting this regional immuno-oncology therapy market.

The global immuno-oncology therapy market is segmented as follows:

By Therapy

  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
    • PD1/ PDL1
    • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Others

By Therapeutic Area

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Melanoma
  • Blood Cancer
  • Other Cancers

By End-User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Cancer Research Institutes

By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com

Download Brochure
Latest Published Reports

View All Published Reports